4.7 Article

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD

期刊

MOLECULAR ONCOLOGY
卷 17, 期 7, 页码 1402-1418

出版社

WILEY
DOI: 10.1002/1878-0261.13368

关键词

acute myeloid leukemia; FLT3-ITD; homoharringtonine; novel BRD4 Inhibitor ACC010

类别

向作者/读者索取更多资源

In this study, the synergistic lethal effects of a novel BRD4 inhibitor (ACC010) and HHT in treating AML were explored. The co-treatment of ACC010 and HHT showed synergistic inhibition of cell proliferation, induction of apoptosis, and cell cycle arrest in FLT3-ITD-positive AML cells in vitro, as well as significant inhibition of AML progression in vivo. These findings suggest that the combination treatment of ACC010 and HHT could be a promising strategy for AML patients, particularly those with FLT3-ITD.
Bromodomain-containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/beta-catenin pathway. Meanwhile, homoharringtonine (HHT), a classic antileukemia drug, possibly inhibits the WNT/beta-catenin pathway. In this study, we attempted to combine a novel BRD4 inhibitor (ACC010) and HHT to explore their synergistic lethal effects in treating AML. Here, we found that co-treatment with ACC010 and HHT synergistically inhibited cell proliferation, induced apoptosis, and arrested the cell cycle in FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive AML cells in vitro, and significantly inhibiting AML progression in vivo. Mechanistically, ACC010 and HHT cooperatively downregulated MYC and inhibited FLT3 activation. Further, when HHT was added, ACC010-resistant cells demonstrated a good synergy. We also extended our study to the mouse BaF3 cell line with FLT3-inhibitor-resistant FLT3-ITD/tyrosine kinase domain mutations and AML cells without FLT3-ITD. Collectively, our results suggested that the combination treatment of ACC010 and HHT might be a promising strategy for AML patients, especially those carrying FLT3-ITD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据